Stockscreener 앱 받기
0.993
1.68%
-0.017
시간 외 거래:
1.01
0.017
+1.71%
전일 마감가:
$1.01
열려 있는:
$0.99
하루 거래량:
698.39K
Relative Volume:
1.00
시가총액:
$78.11M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-1.1821
EPS:
-0.84
순현금흐름:
$-56.88M
1주 성능:
-0.60%
1개월 성능:
-13.65%
6개월 성능:
-77.58%
1년 성능:
-21.19%
1일 변동 폭
$0.99
$1.01
1주일 범위
$0.9886
$1.07
52주 변동 폭
$0.9882
$5.85
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St
CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India
CytomX stock plunges to 52-week low at $1.03 amid market challenges By Investing.com - Investing.com South Africa
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat
CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily
Trading Day Triumph: CytomX Therapeutics Inc (CTMX) Ends at 1.09, a -5.22 Surge/Plunge - The Dwinnex
CTMX Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
Squarepoint Ops LLC Has $243,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News
Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com
CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily
Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News
Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News
Metastatic Cancer Drugs Market Outlook, Insights, and Size: 2024-2033 - WhaTech
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex
Altamira Therapeutics Reports Narrowed Losses - TipRanks
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan
This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat
Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat
Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World
622,616 Shares in ChampionX Co. (NASDAQ:CHX) Bought by Renaissance Technologies LLC - Defense World
Coherent (COHR) Soars 6.3%: Is Further Upside Left in the Stock? - Yahoo Finance
CTMX: A Tale of Ups & Downs – -48.46% loss in 6 Months, -5.65% in 30 Days - The InvestChronicle
Insider Selling: Landau Jeffrey B, CytomX Therapeutics Inc [CTMX] Chief Business Officer divested 4,181 shares - Knox Daily
Choreo LLC Purchases Shares of 23,033 Coty Inc. (NYSE:COTY) - Defense World
Top 2% Biotech Hits Slam Dunk On Bid To Edge Out Bristol, Cytokinetics - Investor's Business Daily
Coherent Corp (COHR)’s Market Momentum: Closing Strong at 80.98, Up 3.93 - The Dwinnex
Autolus Therapeutics (AUTL) Appoints Matthias Will as Chief Development Officer - StreetInsider.com
Analyzing CTMX’s price-to-book ratio for the last quarter - US Post News
Altamira Therapeutics prices up to $12M public offering - MSN
Keeping an Eye on CytomX Therapeutics Inc (CTMX) After Insider Trading Activity - Knox Daily
Check Out CytomX Therapeutics Inc (CTMX)’s Trade Data Rather Than the Analysts’ Views - SETE News
Gaining Ground: CytomX Therapeutics Inc (CTMX) Closes Lower at 1.23, Down -1.60 - The Dwinnex
HC Wainwright Reaffirms Neutral Rating for CytomX Therapeutics (NASDAQ:CTMX) - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Earns Neutral Rating from HC Wainwright - MarketBeat
Acadian Asset Management LLC Acquires 37,739 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Candriam S.C.A. Invests $256,000 in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Market Watch Highlights: CytomX Therapeutics Inc (CTMX) Ends on an Upturn Note at 1.31 - The Dwinnex
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytomx Therapeutics Inc 주식 (CTMX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Landau Jeffrey B | Chief Business Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
119,056 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
179,829 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
175,648 |
| ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
134,978 |
| ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
130,797 |
| Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
6,875 |
0 |
110,061 |
| Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Sale |
1.23 |
1,984 |
2,439 |
108,077 |
| McCarthy Sean A. | CEO |
Aug 20 '24 |
Option Exercise |
0.00 |
37,500 |
0 |
671,749 |
| McCarthy Sean A. | CEO |
Aug 20 '24 |
Sale |
1.23 |
13,898 |
17,082 |
657,851 |
| McCarthy Sean A. | CEO |
Mar 26 '24 |
Option Exercise |
1.57 |
109,768 |
172,874 |
634,249 |
2.02%
0.47%
자본화:
|
볼륨(24시간):